-
2
-
-
84878169183
-
Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management
-
A. Tefferi Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management Am J Hematol 88 2013 507 516
-
(2013)
Am J Hematol
, vol.88
, pp. 507-516
-
-
Tefferi, A.1
-
3
-
-
17844383458
-
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
-
C. James, V. Ugo, J.P.L. Couedic, and et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 2005 1144 1148
-
(2005)
Nature
, vol.434
, pp. 1144-1148
-
-
James, C.1
Ugo, V.2
Couedic, J.P.L.3
-
4
-
-
17644424955
-
A gain-of-function mutation of JAK2 in myeloproliferative disorders
-
R. Kralovics, F. Passamonti, A. Buser, and et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 2005 1779 1790
-
(2005)
N Engl J Med
, vol.352
, pp. 1779-1790
-
-
Kralovics, R.1
Passamonti, F.2
Buser, A.3
-
5
-
-
79551575494
-
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
-
A. Quintas-Cardama, H. Kantarjian, J. Cortes, and et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond Nat Rev Drug Discov 10 2011 127 140
-
(2011)
Nat Rev Drug Discov
, vol.10
, pp. 127-140
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
Cortes, J.3
-
6
-
-
84863393110
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
-
S. Verstovsek, R. Mesa, J. Gotlib, and et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 2012 799 807
-
(2012)
N Engl J Med
, vol.366
, pp. 799-807
-
-
Verstovsek, S.1
Mesa, R.2
Gotlib, J.3
-
7
-
-
84857837774
-
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
-
C. Harrison, J. Kiladjian, H. Al-Ali, and et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 2012 787 798
-
(2012)
N Engl J Med
, vol.366
, pp. 787-798
-
-
Harrison, C.1
Kiladjian, J.2
Al-Ali, H.3
-
8
-
-
0026551775
-
Incidence of polycythemia vera in a defined population
-
S. Berglund, and O. Zettervall Incidence of polycythemia vera in a defined population Eur J Haematol 48 1992 20 26
-
(1992)
Eur J Haematol
, vol.48
, pp. 20-26
-
-
Berglund, S.1
Zettervall, O.2
-
9
-
-
0025820104
-
Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
-
C. Rozman, M. Giralt, E. Feliu, and et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders Cancer 67 1991 2658 2663
-
(1991)
Cancer
, vol.67
, pp. 2658-2663
-
-
Rozman, C.1
Giralt, M.2
Feliu, E.3
-
10
-
-
8344229870
-
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
-
F. Passamonti, E. Rumi, E. Pungolino, and et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia Am J Med 117 2004 755 761
-
(2004)
Am J Med
, vol.117
, pp. 755-761
-
-
Passamonti, F.1
Rumi, E.2
Pungolino, E.3
-
11
-
-
84865193045
-
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study
-
M. Hultcrantz, S.Y. Kristinsson, T.M. Andersson, and et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study J Clin Oncol 30 2012 2995 3001
-
(2012)
J Clin Oncol
, vol.30
, pp. 2995-3001
-
-
Hultcrantz, M.1
Kristinsson, S.Y.2
Andersson, T.M.3
-
12
-
-
84900866397
-
How common are myeloproliferative neoplasms? A systematic review and meta-analysis
-
G.J. Titmarsh, A.S. Duncombe, M.F. McMullin, and et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis Am J Hematol 89 2014 581 587
-
(2014)
Am J Hematol
, vol.89
, pp. 581-587
-
-
Titmarsh, G.J.1
Duncombe, A.S.2
McMullin, M.F.3
-
13
-
-
84896548818
-
Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
-
O. Moulard, J. Mehta, J. Fryzek, and et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union Eur J Haematol 92 2014 289 297
-
(2014)
Eur J Haematol
, vol.92
, pp. 289-297
-
-
Moulard, O.1
Mehta, J.2
Fryzek, J.3
-
14
-
-
33846266634
-
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients
-
R.A. Mesa, J. Niblack, M. Wadleigh, and et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients Cancer 109 2007 68 76
-
(2007)
Cancer
, vol.109
, pp. 68-76
-
-
Mesa, R.A.1
Niblack, J.2
Wadleigh, M.3
-
15
-
-
20244389579
-
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
-
R. Marchioli, G. Finazzi, R. Landolfi, and et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera J Clin Oncol 23 2005 2224 2232
-
(2005)
J Clin Oncol
, vol.23
, pp. 2224-2232
-
-
Marchioli, R.1
Finazzi, G.2
Landolfi, R.3
-
16
-
-
79960437973
-
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients
-
R. Scherber, A.C. Dueck, P. Johansson, and et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients Blood 118 2011 401 408
-
(2011)
Blood
, vol.118
, pp. 401-408
-
-
Scherber, R.1
Dueck, A.C.2
Johansson, P.3
-
17
-
-
84869381382
-
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs
-
R.M. Emanuel, A.C. Dueck, H.L. Geyer, and et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs J Clin Oncol 30 2012 4098 4103
-
(2012)
J Clin Oncol
, vol.30
, pp. 4098-4103
-
-
Emanuel, R.M.1
Dueck, A.C.2
Geyer, H.L.3
-
18
-
-
34249949626
-
Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
-
A. Tefferi, and M. Elliott Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F Semin Thromb Hemost 33 2007 313 320
-
(2007)
Semin Thromb Hemost
, vol.33
, pp. 313-320
-
-
Tefferi, A.1
Elliott, M.2
-
19
-
-
84883273483
-
Splanchnic vein thrombosis in myeloproliferative neoplasms
-
M. Sekhar, K. McVinnie, and A.K. Burroughs Splanchnic vein thrombosis in myeloproliferative neoplasms Br J Haematol 162 2013 730 747
-
(2013)
Br J Haematol
, vol.162
, pp. 730-747
-
-
Sekhar, M.1
McVinnie, K.2
Burroughs, A.K.3
-
20
-
-
67049173799
-
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis
-
F. Dentali, A. Squizzato, L. Brivio, and et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis Blood 113 2009 5617 5623
-
(2009)
Blood
, vol.113
, pp. 5617-5623
-
-
Dentali, F.1
Squizzato, A.2
Brivio, L.3
-
21
-
-
84879104781
-
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera
-
B.L. Stein, S. Saraf, U. Sobol, and et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera Leuk Lymphoma 54 2013 1989 1995
-
(2013)
Leuk Lymphoma
, vol.54
, pp. 1989-1995
-
-
Stein, B.L.1
Saraf, S.2
Sobol, U.3
-
22
-
-
84869175457
-
Polycythemia vera: gender-related phenotypic differences
-
R. Landolfi, L. Di Gennaro, M.A. Nicolazzi, and et al. Polycythemia vera: gender-related phenotypic differences Int Emerg Med 7 2012 509 515
-
(2012)
Int Emerg Med
, vol.7
, pp. 509-515
-
-
Landolfi, R.1
Di Gennaro, L.2
Nicolazzi, M.A.3
-
23
-
-
0036911075
-
Portal vein thrombosis after splenectomy
-
E.R. Winslow, L.M. Brunt, J.A. Drebin, and et al. Portal vein thrombosis after splenectomy Am J Surg 184 2002 631 636
-
(2002)
Am J Surg
, vol.184
, pp. 631-636
-
-
Winslow, E.R.1
Brunt, L.M.2
Drebin, J.A.3
-
24
-
-
33749028699
-
The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera
-
J.J. Michiels, Z. Berneman, W. Schroyens, and et al. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera Semin Thromb Hemost 32 2006 589 604
-
(2006)
Semin Thromb Hemost
, vol.32
, pp. 589-604
-
-
Michiels, J.J.1
Berneman, Z.2
Schroyens, W.3
-
25
-
-
34248364065
-
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
-
R.A. Mesa, S. Verstovsek, F. Cervantes, and et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) Leuk Res 31 2007 737 740
-
(2007)
Leuk Res
, vol.31
, pp. 737-740
-
-
Mesa, R.A.1
Verstovsek, S.2
Cervantes, F.3
-
26
-
-
84859238493
-
Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
-
M.N. Kundranda, R. Tibes, and R.A. Mesa Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? Curr Hematol Malig Rep 7 2012 78 86
-
(2012)
Curr Hematol Malig Rep
, vol.7
, pp. 78-86
-
-
Kundranda, M.N.1
Tibes, R.2
Mesa, R.A.3
-
27
-
-
84887345428
-
Myeloproliferative neoplasms and thrombosis
-
T. Barbui, G. Finazzi, and A. Falanga Myeloproliferative neoplasms and thrombosis Blood 122 2013 2176 2184
-
(2013)
Blood
, vol.122
, pp. 2176-2184
-
-
Barbui, T.1
Finazzi, G.2
Falanga, A.3
-
28
-
-
0018181405
-
Vascular occlusive episodes and venous haematocrit in primary myeloproliferative polychytemia
-
T.C. Pearson, and G. Wetherley-Mein Vascular occlusive episodes and venous haematocrit in primary myeloproliferative polychytemia Lancet 2 1978 1219 1222
-
(1978)
Lancet
, vol.2
, pp. 1219-1222
-
-
Pearson, T.C.1
Wetherley-Mein, G.2
-
29
-
-
33947208087
-
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
-
R. Landolfi, L. Di Gennaro, T. Barbui, and et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera Blood 109 2007 2446 2452
-
(2007)
Blood
, vol.109
, pp. 2446-2452
-
-
Landolfi, R.1
Di Gennaro, L.2
Barbui, T.3
-
30
-
-
84883742082
-
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
-
A. Tefferi, E. Rumi, G. Finazzi, and et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study Leukemia 27 2013 1874 1881
-
(2013)
Leukemia
, vol.27
, pp. 1874-1881
-
-
Tefferi, A.1
Rumi, E.2
Finazzi, G.3
-
31
-
-
79551607979
-
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
-
F. Passamonti, C. Elena, S. Schnittger, and et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations Blood 117 2011 2813 2816
-
(2011)
Blood
, vol.117
, pp. 2813-2816
-
-
Passamonti, F.1
Elena, C.2
Schnittger, S.3
-
32
-
-
0000520406
-
Effect of therapy on blood volume, blood pressure, and splen size in polycythemia vera
-
T.C. Prentice, N.I. Berlin, and J.H. Lawrence Effect of therapy on blood volume, blood pressure, and splen size in polycythemia vera Arch Intern Med 89 1952 584 590
-
(1952)
Arch Intern Med
, vol.89
, pp. 584-590
-
-
Prentice, T.C.1
Berlin, N.I.2
Lawrence, J.H.3
-
33
-
-
79551491928
-
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet
-
T. Barbui, G. Barosi, G. Birgegard, and et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet J Clin Oncol 29 2011 761 770
-
(2011)
J Clin Oncol
, vol.29
, pp. 761-770
-
-
Barbui, T.1
Barosi, G.2
Birgegard, G.3
-
34
-
-
0022743990
-
Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera
-
A.P. Tartaglia, J.D. Goldberg, P.D. Berk, and et al. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera Semin Hematol 23 1986 172 176
-
(1986)
Semin Hematol
, vol.23
, pp. 172-176
-
-
Tartaglia, A.P.1
Goldberg, J.D.2
Berk, P.D.3
-
35
-
-
0028354308
-
Aspirin as an antiplatelet drug
-
C. Patrono Aspirin as an antiplatelet drug N Engl J Med 330 1994 1287 1294
-
(1994)
N Engl J Med
, vol.330
, pp. 1287-1294
-
-
Patrono, C.1
-
36
-
-
84983134916
-
Low-dose aspirin in polycythaemia vera: a pilot study
-
GISP. Low-dose aspirin in polycythaemia vera: a pilot study Br J Haematol 97 1997 453 456
-
(1997)
Br J Haematol
, vol.97
, pp. 453-456
-
-
GISP1
-
37
-
-
0346727336
-
Efficacy and safety of low-dose aspirin in polycythemia vera
-
R. Landolfi, R. Marchioli, J. Kutti, and et al. Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med 350 2004 114 124
-
(2004)
N Engl J Med
, vol.350
, pp. 114-124
-
-
Landolfi, R.1
Marchioli, R.2
Kutti, J.3
-
38
-
-
0017371237
-
Cerebral blood-flow in polycythaemia
-
D.J. Thomas, G.H. du Boulay, J. Marshall, and et al. Cerebral blood-flow in polycythaemia Lancet 2 1977 161 163
-
(1977)
Lancet
, vol.2
, pp. 161-163
-
-
Thomas, D.J.1
Du Boulay, G.H.2
Marshall, J.3
-
39
-
-
0022703490
-
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
-
P.D. Berk, J.D. Goldberg, P.B. Donovan, and et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols Semin Hematol 23 1986 132 143
-
(1986)
Semin Hematol
, vol.23
, pp. 132-143
-
-
Berk, P.D.1
Goldberg, J.D.2
Donovan, P.B.3
-
40
-
-
84871746842
-
Cardiovascular events and intensity of treatment in polycythemia vera
-
R. Marchioli, G. Finazzi, G. Specchia, and et al. Cardiovascular events and intensity of treatment in polycythemia vera N Engl J Med 368 2013 22 33
-
(2013)
N Engl J Med
, vol.368
, pp. 22-33
-
-
Marchioli, R.1
Finazzi, G.2
Specchia, G.3
-
41
-
-
66549086134
-
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
-
G. Barosi, G. Birgegard, G. Finazzi, and et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference Blood 113 2009 4829 4833
-
(2009)
Blood
, vol.113
, pp. 4829-4833
-
-
Barosi, G.1
Birgegard, G.2
Finazzi, G.3
-
42
-
-
84856866188
-
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
-
A. Alvarez-Larran, A. Pereira, F. Cervantes, and et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera Blood 119 2012 1363 1369
-
(2012)
Blood
, vol.119
, pp. 1363-1369
-
-
Alvarez-Larran, A.1
Pereira, A.2
Cervantes, F.3
-
43
-
-
84881065384
-
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
-
G. Barosi, R. Mesa, G. Finazzi, and et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project Blood 121 2013 4778 4781
-
(2013)
Blood
, vol.121
, pp. 4778-4781
-
-
Barosi, G.1
Mesa, R.2
Finazzi, G.3
-
44
-
-
84876138022
-
Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms
-
B.L. Stein, and R.V. Tiu Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms J Interferon Cytokine Res 33 2013 145 153
-
(2013)
J Interferon Cytokine Res
, vol.33
, pp. 145-153
-
-
Stein, B.L.1
Tiu, R.V.2
-
45
-
-
0018098799
-
Interferon affects both G1 and S + G2 in cells stimulated from quiescence to growth
-
F. Balkwill, and J. Taylor-Papadimitriou Interferon affects both G1 and S + G2 in cells stimulated from quiescence to growth Nature 274 1978 798 800
-
(1978)
Nature
, vol.274
, pp. 798-800
-
-
Balkwill, F.1
Taylor-Papadimitriou, J.2
-
46
-
-
0029997033
-
Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest
-
N. Tiefenbrun, D. Melamed, N. Levy, and et al. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest Mol Cell Biol 16 1996 3934 3944
-
(1996)
Mol Cell Biol
, vol.16
, pp. 3934-3944
-
-
Tiefenbrun, N.1
Melamed, D.2
Levy, N.3
-
47
-
-
79951740151
-
Type I interferon inhibits interleukin-1 production and inflammasome activation
-
G. Guarda, M. Braun, F. Staehli, and et al. Type I interferon inhibits interleukin-1 production and inflammasome activation Immunity 34 2011 213 223
-
(2011)
Immunity
, vol.34
, pp. 213-223
-
-
Guarda, G.1
Braun, M.2
Staehli, F.3
-
48
-
-
77951491478
-
Recent advances on the immunomodulatory effects of IFN-A: implications for cancer immunotherapy and autoimmunity
-
P. Rizza Recent advances on the immunomodulatory effects of IFN-A: implications for cancer immunotherapy and autoimmunity Autoimmunity 43 2010 204 209
-
(2010)
Autoimmunity
, vol.43
, pp. 204-209
-
-
Rizza, P.1
-
49
-
-
77952955507
-
Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
-
M. Lu, W. Zhang, Y. Li, and et al. Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway Exp Hematol 38 2010 472 480
-
(2010)
Exp Hematol
, vol.38
, pp. 472-480
-
-
Lu, M.1
Zhang, W.2
Li, Y.3
-
50
-
-
0022338499
-
Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses
-
W. Linkesch, H. Gisslinger, H. Ludwig, and et al. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses] Acta Med Austriaca 12 1985 123 127
-
(1985)
Acta Med Austriaca
, vol.12
, pp. 123-127
-
-
Linkesch, W.1
Gisslinger, H.2
Ludwig, H.3
-
51
-
-
0022359194
-
Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases
-
H. Ludwig, A. Cortelezzi, B.G. Van Camp, and et al. Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases Oncology 42 suppl 1 1985 19 25
-
(1985)
Oncology
, vol.42
, pp. 19-25
-
-
Ludwig, H.1
Cortelezzi, A.2
Van Camp, B.G.3
-
52
-
-
0023688229
-
Recombinant interferon-alpha for treatment of polycythaemia vera
-
R.T. Silver Recombinant interferon-alpha for treatment of polycythaemia vera Lancet 2 1988 403
-
(1988)
Lancet
, vol.2
, pp. 403
-
-
Silver, R.T.1
-
53
-
-
33746307253
-
Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha
-
R.T. Silver Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha Cancer 107 2006 451 458
-
(2006)
Cancer
, vol.107
, pp. 451-458
-
-
Silver, R.T.1
-
54
-
-
79955947379
-
The renaissance of interferon therapy for the treatment of myeloid malignancies
-
J.J. Kiladjian, R.A. Mesa, and R. Hoffman The renaissance of interferon therapy for the treatment of myeloid malignancies Blood 117 2011 4706 4715
-
(2011)
Blood
, vol.117
, pp. 4706-4715
-
-
Kiladjian, J.J.1
Mesa, R.A.2
Hoffman, R.3
-
55
-
-
81255210738
-
A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms
-
H.C. Hasselbalch A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms Expert Rev Hematol 4 2011 637 655
-
(2011)
Expert Rev Hematol
, vol.4
, pp. 637-655
-
-
Hasselbalch, H.C.1
-
56
-
-
51549092094
-
The impact of PEGylation on biological therapies
-
F.M. Veronese, and A. Mero The impact of PEGylation on biological therapies BioDrugs 22 2008 315 329
-
(2008)
BioDrugs
, vol.22
, pp. 315-329
-
-
Veronese, F.M.1
Mero, A.2
-
57
-
-
54049141336
-
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
-
J.J. Kiladjian, B. Cassinat, S. Chevret, and et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera Blood 112 2008 3065 3072
-
(2008)
Blood
, vol.112
, pp. 3065-3072
-
-
Kiladjian, J.J.1
Cassinat, B.2
Chevret, S.3
-
58
-
-
84872383163
-
Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon {alpha}-2a (peg-IFN{alpha}-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial
-
P. Turlure, N. Cambier, M. Roussel, and et al. Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon {alpha}-2a (peg-IFN{alpha}-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial ASH Annual Meeting Abstracts 118 2011 280
-
(2011)
ASH Annual Meeting Abstracts
, vol.118
, pp. 280
-
-
Turlure, P.1
Cambier, N.2
Roussel, M.3
-
59
-
-
73949090770
-
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
-
A. Quintas-Cardama, H. Kantarjian, T. Manshouri, and et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera J Clin Oncol 27 2009 5418 5424
-
(2009)
J Clin Oncol
, vol.27
, pp. 5418-5424
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
Manshouri, T.3
-
60
-
-
84883185991
-
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
-
A. Quintás-Cardama, O. Abdel-Wahab, T. Manshouri, and et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a Blood 122 2013 893 901
-
(2013)
Blood
, vol.122
, pp. 893-901
-
-
Quintás-Cardama, A.1
Abdel-Wahab, O.2
Manshouri, T.3
-
61
-
-
84867261125
-
Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
-
K. Gowin, P. Thapaliya, J. Samuelson, and et al. Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients Haematologica 97 2012 1570 1573
-
(2012)
Haematologica
, vol.97
, pp. 1570-1573
-
-
Gowin, K.1
Thapaliya, P.2
Samuelson, J.3
-
62
-
-
0037217859
-
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia
-
Y. Alvarado, J. Cortes, S. Verstovsek, and et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia Cancer Chemother Phamacol 51 2003 81 86
-
(2003)
Cancer Chemother Phamacol
, vol.51
, pp. 81-86
-
-
Alvarado, Y.1
Cortes, J.2
Verstovsek, S.3
-
63
-
-
33646470836
-
A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life
-
J. Samuelsson, H. Hasselbalch, O. Bruserud, and et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life Cancer 106 2006 2397 2405
-
(2006)
Cancer
, vol.106
, pp. 2397-2405
-
-
Samuelsson, J.1
Hasselbalch, H.2
Bruserud, O.3
-
64
-
-
35648966599
-
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study
-
E. Jabbour, H. Kantarjian, J. Cortes, and et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study Cancer 110 2007 2012 2018
-
(2007)
Cancer
, vol.110
, pp. 2012-2018
-
-
Jabbour, E.1
Kantarjian, H.2
Cortes, J.3
-
65
-
-
84892184457
-
AOP2014, a novel peg-proline-interferon alpha-2b with improved pharmacokinetic properties, is safe and well tolerated and shows promising efficacy in patients with polycythemia vera (PV)
-
H. Gisslinger, R. Kralovics, and B. Gisslinger AOP2014, a novel peg-proline-interferon alpha-2b with improved pharmacokinetic properties, is safe and well tolerated and shows promising efficacy in patients with polycythemia vera (PV) Blood 120 suppl 1 2012 175
-
(2012)
Blood
, vol.120
, pp. 175
-
-
Gisslinger, H.1
Kralovics, R.2
Gisslinger, B.3
-
66
-
-
20144389274
-
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
-
G. Finazzi, V. Caruso, R. Marchioli, and et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study Blood 105 2005 2664 2670
-
(2005)
Blood
, vol.105
, pp. 2664-2670
-
-
Finazzi, G.1
Caruso, V.2
Marchioli, R.3
-
67
-
-
79959203501
-
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms
-
M. Bjorkholm, A.R. Derolf, M. Hultcrantz, and et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms J Clin Oncol 29 2011 2410 2415
-
(2011)
J Clin Oncol
, vol.29
, pp. 2410-2415
-
-
Bjorkholm, M.1
Derolf, A.R.2
Hultcrantz, M.3
-
68
-
-
84922264206
-
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
-
A. Alvarez-Larrán, L. Martínez-Avilés, J.C. Hernández-Boluda, and et al. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea Ann Hematol 93 2014 2037 2043
-
(2014)
Ann Hematol
, vol.93
, pp. 2037-2043
-
-
Alvarez-Larrán, A.1
Martínez-Avilés, L.2
Hernández-Boluda, J.C.3
-
69
-
-
80053945428
-
Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980
-
J.J. Kiladjian, S. Chevret, C. Dosquet, and et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980 J Clin Oncol 29 2011 3907 3913
-
(2011)
J Clin Oncol
, vol.29
, pp. 3907-3913
-
-
Kiladjian, J.J.1
Chevret, S.2
Dosquet, C.3
-
70
-
-
84893733177
-
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
-
S. Verstovsek, F. Passamonti, A. Rambaldi, and et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea Cancer 120 2014 513 520
-
(2014)
Cancer
, vol.120
, pp. 513-520
-
-
Verstovsek, S.1
Passamonti, F.2
Rambaldi, A.3
-
71
-
-
84939611890
-
Ruxolitinib in polycythemia vera resistant to or intolerant of hydroxyurea
-
In press
-
Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib in polycythemia vera resistant to or intolerant of hydroxyurea. N Engl J Med. In press.
-
N Engl J Med
-
-
Vannucchi, A.M.1
Kiladjian, J.J.2
Griesshammer, M.3
-
72
-
-
84855464431
-
Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms
-
V. Skov, T.S. Larsen, M. Thomassen, and et al. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms Leuk Lymphoma 53 2012 123 129
-
(2012)
Leuk Lymphoma
, vol.53
, pp. 123-129
-
-
Skov, V.1
Larsen, T.S.2
Thomassen, M.3
-
73
-
-
33748135979
-
Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules
-
S. Carta, S. Tassi, C. Semino, and et al. Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules Blood 108 2006 1618 1626
-
(2006)
Blood
, vol.108
, pp. 1618-1626
-
-
Carta, S.1
Tassi, S.2
Semino, C.3
-
74
-
-
34548125345
-
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells
-
J. Golay, L. Cuppini, F. Leoni, and et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells Leukemia 21 2007 1892 1900
-
(2007)
Leukemia
, vol.21
, pp. 1892-1900
-
-
Golay, J.1
Cuppini, L.2
Leoni, F.3
-
75
-
-
40749113668
-
Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells
-
V. Barbetti, A. Gozzini, E. Rovida, and et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells Oncogene 27 2008 1767 1778
-
(2008)
Oncogene
, vol.27
, pp. 1767-1778
-
-
Barbetti, V.1
Gozzini, A.2
Rovida, E.3
-
76
-
-
42349087790
-
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)
-
V. Guerini, V. Barbui, O. Spinelli, and et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F) Leukemia 22 2008 740 747
-
(2008)
Leukemia
, vol.22
, pp. 740-747
-
-
Guerini, V.1
Barbui, V.2
Spinelli, O.3
-
77
-
-
77955168425
-
A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
-
A. Rambaldi, C.M. Dellacasa, G. Finazzi, and et al. A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms Br J Haematol 150 2010 446 455
-
(2010)
Br J Haematol
, vol.150
, pp. 446-455
-
-
Rambaldi, A.1
Dellacasa, C.M.2
Finazzi, G.3
-
78
-
-
84877814233
-
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
-
G. Finazzi, A.M. Vannucchi, V. Martinelli, and et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy Br J Haematol 161 2013 688 694
-
(2013)
Br J Haematol
, vol.161
, pp. 688-694
-
-
Finazzi, G.1
Vannucchi, A.M.2
Martinelli, V.3
-
79
-
-
84860316991
-
Efficacy of vorinostat in a murine model of polycythemia vera
-
H. Akada, S. Akada, A. Gajra, and et al. Efficacy of vorinostat in a murine model of polycythemia vera Blood 119 2012 3779 3789
-
(2012)
Blood
, vol.119
, pp. 3779-3789
-
-
Akada, H.1
Akada, S.2
Gajra, A.3
-
80
-
-
84880658117
-
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
-
C.L. Andersen, M.F. McMullin, E. Ejerblad, and et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia Br J Haematol 162 2013 498 508
-
(2013)
Br J Haematol
, vol.162
, pp. 498-508
-
-
Andersen, C.L.1
McMullin, M.F.2
Ejerblad, E.3
|